Friday, September 11, 2009

Generex Announces USFDA Approval Of Use Of Company’s Flagship Buccal Insulin Product, Generex Oral-Lyn under Treatment IND Program

Generex Biotechnology Corporation the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the treatment use of Generex Oral-lyn™ under the FDA’s Treatment Investigational New Drug (IND) program.

the details can be read here.

No comments: